ArticleBMC public health2025
Effects of oral zinc supplementation in the prevention of community-acquired pneumonia in colombian children: an economic evaluation : Short running title: Cost-effectiveness analysis oral zinc supplementation.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- How does digital financial inclusion affect the health of older adults? Evidence from China.SSM - population health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOral zinc supplementation is a well-known intervention, widely used to prevent infectious diseases. However, it is also necessary to demonstrate that it achieves the maximum benefit at the lowest possible cost in pneumonia in children, particularly in low- and middle-income countries. This economic evaluation aims to estimate the cost-utility and cost-effectiveness of zinc supplementation for the prevention of community-acquired pneumonia in children aged 1 to 6 years in Colombia. MATERIALS AND
methodsUsing the decision tree analysis, we estimated the expected benefits and costs of zinc supplementation versus no supplementation based on data on effectiveness and cost previously published in Colombia. The perspective of the present economic evaluation is the perspective of society with a time horizon of 1 year.
resultsThe net monetary benefit (NMB) with oral zinc supplementation was US$ 5,063.3 (95% UI: 5,061–5,065), compared to US$ 5,062.6 (95% UI: 5,060–5,064) without supplementation. The estimated cost effectiveness ratio was U$ 4 873 per QALY and U$ 10 324 per year lived gained. In the probabilistic sensitivity analysis, oral zinc supplementation was the most cost-effective therapy in the 53.4% of replications at willingness-to-pay (WTP) of U$ 5180 values.
conclusionIn conclusion, oral zinc supplementation in children aged 1 to 6 years in Colombia appears to be a potentially cost-effective strategy for the prevention of community-acquired pneumonia compared to non-supplementation. These findings should be interpreted with caution given the small absolute difference in benefits and the marginal incremental net monetary benefit observed. This result becomes an input for the construction of public health policies aimed at reducing the burden of disease generated by respiratory infections in Colombia, as well as serving as an example and motivation to assess the cost and utility of these strategies in other developing and developed countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.